Clinical trials have shown that patients taking Wegovy (semaglutide) at the maintenance dose of 2.4mg lost an average of 15% to 21% of their body weight over 68 weeks when combined with diet and exercise
Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with Wegovy Warnings and Precautions Risk of Thyroid C-Cell Tumors : Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging Acute Pancreatitis : Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including Wegovy
If you choose the upper arm as your injection site, you might need help from a friend, family member, or healthcare professional to inject properly
Wegovy is specifically designed for weight management in overweight or obese individuals with or without diabetes
cc ca cc oan, bnh nhn b suy dinh dng
The secondary efficacy endpoints included here are as follows: percent change in body weight at week 48